AdvaMed Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
News / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging
AdvaMed Welcomes White House’s “America’s AI Action Plan”
July 23, 2025
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, issued the following statement on the White House’s “America’s AI Action Plan”:
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/18
July 18, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q2 2025 Report
July 17, 2025
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
Resource / Compliance / Government & Legislative Affairs / Legal
AdvaMed Comments to HHS Deregulation RFI
July 14, 2025
AdvaMed submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/11
July 11, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 11, 2025.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Kennedy v Braidwood Ruling: What’s Next for MedTech
July 17, 2025
2:00 PM – 3:30 PM
Join AdvaMed and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
News / Government & Legislative Affairs
AdvaMed Statement on the Tax Bill
July 3, 2025
WASHINGTON – Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the impact the “One Big Beautiful Bill Act” will have on medtech innovation.
Resource / Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs
Supreme Court’s Decision in Kennedy v. Braidwood Management, Inc.
July 2, 2025
Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.